Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975153 · ClinicalTrials.gov registry record · Phase 2
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03975153 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 15 participants.
The verdict
NCT03975153, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Interventions
- BIOLOGICAL guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-10-03 |
| Est. Completion | 2024-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03975153
The ClinicalTrials.gov registry entry for NCT03975153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which guselkumab is the first listed.
NCT03975153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03975153 about?
NCT03975153 is a clinical study titled "Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)". 15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoc...
What is the current status of trial NCT03975153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-10-03. Estimated completion is 2024-03-22.
What interventions are being tested in trial NCT03975153?
The interventions under investigation include: guselkumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03975153?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.